<?xml version="1.0" encoding="UTF-8"?>
<p id="Par3">As part of an ongoing research project monitoring patients newly started on medications in primary care, data were collected before and during the pandemic. To examine the impact of COVID-19, we obtained IRB approval to expand the study to include two large healthcare institutions during the period of Februaryâ€“May 2020. We also looked at changes in outpatient LDL cholesterol and HbA1c testing and initiation of statin and metformin therapy, as representative initial steps that providers might take to reduce the risk of cardiovascular events or manage diabetes.</p>
